drugset

drugset / Trial / NCT04675450

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

NCT04675450 ↗

Phase 2 Withdrawn Conjupro Biotherapeutics, Inc. CSPC-NBP Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.

Timeline

Start: 2023-06-30
Primary completion: 2024-12-30
Completion: 2025-01-30

Outcome

Outcome not reported

Stopped: “Further preclinical development activities required to proceed”

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	n Butylphthalide	Unknown	400 mg	Oral

Indications